Alnylam Validates Subcutaneous Delivery Technology With Strong Phase I Results
This article was originally published in The Pink Sheet Daily
The RNA interference-focused biotech will bring the rest of its pipeline forward with subcutaneous technology now that it has been validated in human studies, but the company will continue to pursue approval of its lead candidate as an infusion product.
You may also be interested in...
RNAi pioneer is getting closer to market with NDA filing in amyloidosis expected in 2017, but ample competition is coming along, albeit far behind.
At an investor day, the RNAi firm outlined Phase I programs in paroxysmal nocturnal hemoglobinuria, hemophilia and hepatic porphyria, and said it is using a de-risked drug development methodology.
Isis will target its APOCIII candidate to treat extremely and severely high triglycerides first, then move to broader populations. The strategy harkens back to the plan for cholesterol drug Kynamro, which has had a slow launch.